207 related articles for article (PubMed ID: 7692110)
1. Androgen metabolism in men receiving finasteride before prostatectomy.
Norman RW; Coakes KE; Wright AS; Rittmaster RS
J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
3. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
[TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
5. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
6. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
7. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
8. Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.
Marks LS; Hess DL; Dorey FJ; Luz Macairan M; Cruz Santos PB; Tyler VE
Urology; 2001 May; 57(5):999-1005. PubMed ID: 11337315
[TBL] [Abstract][Full Text] [Related]
9. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
[TBL] [Abstract][Full Text] [Related]
10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
11. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
12. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
[TBL] [Abstract][Full Text] [Related]
13. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
14. Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor.
Prahalada S; Rhodes L; Grossman SJ; Heggan D; Keenan KP; Cukierski MA; Hoe CM; Berman C; van Zwieten MJ
Prostate; 1998 May; 35(3):157-64. PubMed ID: 9582084
[TBL] [Abstract][Full Text] [Related]
15. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
16. Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate.
Ghanadian R; Puah CM
J Endocrinol; 1981 Feb; 88(2):255-62. PubMed ID: 6162906
[TBL] [Abstract][Full Text] [Related]
17. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
18. Validation of a sequential extraction and liquid chromatography-tandem mass spectrometric method for determination of dihydrotestosterone, androstanediol and androstanediol-glucuronide in prostate tissues.
Adomat HH; Bains OS; Lubieniecka JM; Gleave ME; Guns ES; Grigliatti TA; Reid RE; Riggs KW
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 902():84-95. PubMed ID: 22818945
[TBL] [Abstract][Full Text] [Related]
19. Decreased urinary 5 alpha-androstane-3 alpha,17 beta-diol glucuronide excretion in patients with benign prostatic hyperplasia.
Wright F; Poizat R; Bongini M; Bozzolan F; Doukani A; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1985 Feb; 60(2):294-8. PubMed ID: 2578133
[TBL] [Abstract][Full Text] [Related]
20. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
Hill M; Petrik R; Hampl R; Stárka L
Horm Metab Res; 1996 Oct; 28(10):562-4. PubMed ID: 8934217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
